Comprehensive Therapeutic Protein Characterization Using One Single Method

Jun 19, 2017 | Biopharma, Blogs | 0 comments

Get to know how CESI-MS will allow you to quickly and accurately characterize protein therapeutics for attributes in a single method by downloading this discovery kit.

The Biologics Characterization and Discovery Kit Includes:

  • Executive Summary
  • Tech Note: A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
  • Webinar: Biologics Characterization and Discovery by CESI-MS
  • Tech Note: CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
  • Tech Note: Structural Characterization of ADCs by a Combination of Intact, Middle-up, and Bottom-up Approaches using CESI-MS

A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
Discover how combining the unique separation capabilities of capillary zone electrophoresis (CZE) with the advantages of an MS-based detector provide high-resolution structural information and accurate molecular weight information. Using CESI-MS and stand-alone CE functionality of the CESI 8000 Plus system, researchers demonstrate powerful methods to characterize intact and reduced IgG forms.

CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
Includes a summary of work recently published by the research group LSMIS at the University of Strasbourg. It focuses on how CESI-MS can be used to characterize and compare a marketed reference mAb with other biosimilar candidates. A CESI-MS protocol for biosimilarity studies of mAbs has been developed which highlights 100% amino acid sequence coverage & PTM “hot spot” mapping and ID.

Structural Characterization of Antibody-Drug Conjugates (ADCs) by a Combination of Intact, Middle-up and Bottom-up Approaches using CESI-MS
This tech note also summarizes work recently published by the research group at LSMIS. In this tech note, discover how CESI-MS can be used to characterize a gold standard cysteine-linked ADC, brentuximab vedotin. Want to learn more about highlighting DAR calculation under native conditions; drug distribution, drug location, 100% coverage and PTMs? It’s all here.

Visit our website to learn more about CE instruments >

Pure and simple: Understanding LNP analytics for better mRNA-based drugs

A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.

Is the next life-changing drug waiting to be analyzed in your laboratory?

In drug discovery laboratories, there is often a need to generate trusted analytical data on hundreds of thousands of drug candidates to allow confident decisions to be made. Sample prep, instrument run time, and data processing are all challenges that must be overcome.

Mass spec data across the cultivated meat value chain

We recently had the opportunity to chat with Alex Ward, PhD, Principal Consultant, Arta Bioanalytics to discover more about his work in developing transcriptomics and metabolomics data interpretation for the cultivated meat sector. As a specialist in multi-omics approaches, Alex is driving R&D, production and regulatory processes for the industry. Below are Alex’s responses to a few questions we asked, sharing his knowledge with the SCIEX community to drive the future of cultivated meat.

Posted by

0 Comments

Submit a Comment

Social Share Buttons and Icons powered by Ultimatelysocial